Post by Lydia Ostermeier - Haynes, MSN, RN

The newest episode of Converge, our special series within the Impactful Leaders Podcast, explores one of the most consequential frontiers in medicine: the shift from managing disease to fundamentally altering its trajectory. Host Evan Markou talks with Jerry McLaughlin, CEO of Life Biosciences, whose three decades in biopharma give him a rare longitudinal vantage point on the rise of epigenetic reprogramming. Their conversation traces a profound mindset shift—from slowing decline to reversing it—as advances in epigenetics move from theory into clinical reality. A historic milestone underscores this moment: the first human dosing of an epigenetic restoration therapy for optic neuropathies. McLaughlin frames it as a turning point toward accountability, rigor, and evidence‑based progress in the longevity field. Life Biosciences’ lead program, ER‑100, aims to restore cellular resilience and potentially redefine treatment paradigms for conditions like glaucoma and NAION. Looking ahead, McLaughlin sees a “cornucopia of opportunities” across organ systems—but also a responsibility to let science, not hype, lead. It’s a compelling conversation about ambition, discipline, and the future of healthy human lifespan. 🎙️Tune in: https://lnkd.in/eN5emEPt #ImpactfulLeaders #Podcast #Converge #ER100